Cue Biopharma (CUE) Non-Current Assets (2017 - 2025)

Cue Biopharma has disclosed Non-Current Assets across 9 years of filings, most recently posting $5.2 million for Q4 2025.

• Non-Current Assets for Q4 2025 came in at $5.2 million, down 25.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.2 million (down 15.71% YoY), and the FY2025 annual result was $5.2 million, down 25.86% from the prior year.
• Non-Current Assets came in at $5.2 million for Q4 2025 at Cue Biopharma, down from $5.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $15.7 million in Q2 2022 to a low of $5.2 million in Q4 2025.
• The 5-year median for Non-Current Assets is $10.0 million (2021), against an average of $10.5 million.
• Across the five-year window, Non-Current Assets tumbled 33.97% in 2021 and soared 69.37% in 2022, its largest moves.
• Cue Biopharma's Non-Current Assets stood at $14.9 million in 2021, then dropped by 5.6% to $14.1 million in 2022, then slipped by 28.52% to $10.1 million in 2023, then tumbled by 30.0% to $7.1 million in 2024, then declined by 25.86% to $5.2 million in 2025.
• The last three Non-Current Assets figures came in at $5.2 million (Q4 2025), $5.8 million (Q3 2025), and $9.9 million (Q2 2025), per Business Quant data.